EMV Capital PLC - Portfolio Update: Glycotest and ProAxsis
Strictly embargoed for:
EMV Capital plc
(EMV Capital or EMVC or the Company or the Group)
Glycotest
and
ProAxsis share capital reorganisation, proposed fundraising of up to
EMV Capital plc (AIM: EMVC), the deep tech and life sciences VC investment group, is pleased to announce that Glycotest, Inc. (Glycotest) has successfully closed a first tranche fundraising (Glycotest Fundraising) and ProAxsis Limited (ProAxsis) has completed a share capital reorganisation (ProAxsis Reorganisation) ahead of a planned fundraising, which in each case results in these portfolio companies ceasing to be consolidated subsidiaries of the Group as of
Glycotest Fundraising
The Glycotest Fundraising was led and syndicated by EMV Capital Partners Limited (EMVCP), the Group's wholly owned venture capital and corporate finance firm.
The Glycotest Fundraising totals c.
Glycotest has headroom to close additional funding up to c.
The proceeds from the Glycotest Fundraising will be used for:
· the progression of second-generation glycoproteomic assay development with the University of Georgia Complex Carbohydrate Research Center UGA CCRC - assaying over 1,300 clinical validation study samples to generate the data set required for algorithm training and HCC Panel performance validation;
· preparatory steps toward CLIA lab establishment for a targeted 2027 commercial launch; and
· working capital.
Following the completion of the first closing of the Glycotest Fundraising, the Group's total equity holding in Glycotest is 48.67 per cent. (fully diluted but not including the outstanding balance of the CLA), which equates to a post-investment fair value of
In addition, following the introduction of investors to Glycotest by EMVCP, the Group's third-party assets under management with Glycotest is 48.76 per cent. of Glycotest's share capital (fully diluted but not including the CLA), which equates to a post-investment fair value of c.
It is anticipated that Glycotest will in due course adopt a new share options scheme to replace recently expired options, which options shall amount to 10 per cent. of the issued share capital.
ProAxsis Reorganisation and proposed fundraising
ProAxsis has undertaken the Reorganisation in order allow it to be an Enterprise Investment Scheme (EIS) qualifying company. The Reorganisation included all shareholders of ProAxsis being issued pro-rata with warrants over the share capital of ProAxsis. A condition of exercise of such warrants is that the resulting shareholding of each warrant holder following exercise must be below 50 per cent. of the issued share capital of ProAxsis (Exercise Condition). Accordingly, the Group may only exercise its warrants as and when further shares are issued by ProAxsis.
The result of the Reorganisation is that the Group's total equity holding in ProAxsis is 49.87 per cent. of the issued share capital. For illustration purposes only, if the Exercise Condition was not applicable and the Group exercised its warrants, the Group's total equity holding in ProAxsis would be 82.25 per cent. on a fully diluted basis.
The Reorganisation allows ProAxsis to launch its proposed EIS-qualifying fundraising, also led and syndicated by EMVCP. The proposed fundraising includes an anticipated fundraising of up to
The proceeds from the fundraising will be used by ProAxsis for:
· completion of its clinical study with Imperial College London;
· product development, IP development and equipment purchases;
· commercial scale-up; and
· working capital.
As the issue price of the fundraising is not anticipated to change since the prior ProAxsis fundraising, the Group's direct fair value holding of
Following the introduction of investors to ProAxsis by EMVCP, the Group's third-party assets under management with ProAxsis are anticipated to increase compared to the indirect fair value amount of
It is anticipated that ProAxsis will in due course adopt a new share options scheme, which options shall amount to 10 per cent. of the issued share capital.
Loan Agreement and related party transaction
ProAxsis has also entered into a loan agreement (Loan Agreement) with AB Group Limited (as lender) to refinance an existing AB Group Limited loan (plus accrued interest), totalling in aggregate c.
As AB Group, together with other entities associated with
The Directors of the Company, excluding Dr
Group accounting impact of the Glycotest Fundraising and ProAxsis Reorganisation
As a result of the Group's holdings in each of Glycotest and ProAxsis falling below 50 per cent, management has assessed that the Group no longer exercises control of either company for the purposes of IFRS 10. Accordingly, the Group intends to deconsolidate each of Glycotest and ProAxsis with effect from
Commenting on these transactions, Dr
"These fundraisings represent an important milestone in the evolution of both Glycotest and ProAxsis, marking their transition from incubation to independently funded growth companies. They demonstrate our capital-efficient investment model in action as we bring in third party investors to fund the next stage of development, while retaining meaningful equity positions, board representation and long-term value creation service agreements.
"This approach enables us to recycle capital, support a larger number of portfolio companies, and scale our investment platform without a corresponding increase in balance sheet commitment. It is a core element of EMV Capital's strategy to build and realise value in a disciplined, capital-efficient manner.
"The deconsolidation makes EMV Capital's investment case easier to understand for our shareholders and investors. With both companies now accounted for as investments in associates, our consolidated results will more clearly reflect our core venture capital and fund management operations. Shareholders, equity analysts and co-investors can assess more easily the underlying value and earnings power of the business.
"We remain committed to supporting both Glycotest and ProAxsis through our ongoing board involvement, value creation services and corporate finance advisory relationships as they execute their next phase of growth."
The person responsible for arranging the release of this announcement on behalf of the Company is
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE
-ends-
For more information, please contact:
|
|
|
|
EMV Capital plc |
via Rosewood |
|
|
|
|
|
|
|
Panmure Liberum Limited (NOMAD and Broker) |
+44 (0)20 7886 2500 |
|
|
|
|
|
|
|
|
|
|
Rosewood (Financial PR) |
+44 (0)20 7653 8702 |
|
|
|
About EMV Capital plc (EMVC)
EMV Capital plc, is a deep tech and life sciences venture capital investment group with an international portfolio of high-growth companies. With a focus on generating superior returns for investors from the fast-growing sectors and technologies that will define our future, EMV Capital invests in, manages and strengthens early-stage IP-rich companies.
EMV Capital holds both direct equity stakes and carried interest in its portfolio companies, creating an evergreen structure that supports extensive growth and value creation. EMV Capital's investment thesis is realised through these capital sources:
· capital-efficient investments through Group balance sheet;
· fund management of the Evergreen EIS and Martlet Capital Funds;
· syndicated investments leveraging its network of third-party investors.
EMV Capital's approach is characterised by its proactive management style, aiming to advance portfolio companies to critical value inflection points by actively engaging with them. Companies are supported through Board representation and the use of its Value Creation Services practice.
Headquartered in
About Glycotest
Glycotest is a US-based liver disease diagnostics company commercialising novel and unique blood tests for life threatening liver cancers and fibrosis-cirrhosis. The company was founded in 2012 by EMV Capital (then NetScientific) based on technology originating at the Baruch S. Blumberg Institute and Drexel University College of Medicine.
Glycotest's lead product, the HCC Panel, is a biomarker panel powered by a proprietary algorithm for the early detection of curable, early-stage hepatocellular carcinoma (HCC) - the most common form of primary liver cancer. The HCC Panel has outperformed the current standard of care blood tests in preliminary clinical studies. Glycotest estimates that the early detection market for HCC presents a market opportunity of more than
Glycotest has also developed a blood test for the second most prevalent form of liver cancer, cholangiocarcinoma, and a blood test for staging liver fibrosis.
About ProAxsis
ProAxsis is a commercial biomarker-led research company supporting drug development and clinical research through specialist biomarker insights. A spin-out from Queen's University Belfast, the company has commercialised activity-based immunoassays targeting active Neutrophil Elastase (NE), Proteinase 3 (Pr3) and Cathepsin G (Cat G) as biomarkers of lung infection and inflammation in chronic respiratory diseases such as chronic obstructive pulmonary disease (COPD), bronchiectasis and cystic fibrosis (CF).
This technology has been translated into a point-of-use test (NEATstik®), designed to enable fast, routine assessment of active NE levels.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not registered in any category of registration under the securities legislation of any province or territory of Canada. Nothing in this record constitutes "advice" concerning investing in, buying, or selling a security within the meaning of applicable Canadian securities legislation. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after obtaining advice from a registrant authorised under the securities legislation of your province or territory.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship is for news distribution and media services only and does not determine, influence, or shape the editorial content produced.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE